Singapore markets close in 3 hours 58 minutes

CytoDyn Inc. (CYDY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.2400+0.0325 (+15.66%)
At close: 03:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.2075
Open0.2050
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.2050 - 0.2550
52-week range0.1300 - 0.4200
Volume3,755,452
Avg. volume1,922,570
Market cap238.408M
Beta (5Y monthly)0.25
PE ratio (TTM)N/A
EPS (TTM)-0.0600
Earnings date16 Apr 2024 - 21 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    May 2024 Letter to Shareholders

    VANCOUVER, Washington, May 16, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, I write today to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), as we approach the end of our 2024 fiscal year (May 31, 2024), and to sincerely thank you for your unwavering support. Fiscal year 2024 was a significant year for CytoDyn, and one that I believe will be remembered as the beginning of a turnaround. The Company achieved the lifting of the FDA’s clinical hold in late February 2024 and is now working

  • GlobeNewswire

    CytoDyn Announces FDA Has Lifted Clinical Hold

    Webcast to Provide Company Update on March 5, 2024 VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA has lifted the clinical hold on leronlimab. The Company is now free to proceed with its proposed HIV clinical trial exploring leronlimab and its effects on chronic inflammation. CytoDy

  • GlobeNewswire

    CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

    VANCOUVER, Washington, Feb. 01, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has submitted its revised HIV clinical trial protocol to the FDA. The Company believes this submission will lead to the removal of the clinical hold currently in effect. CytoDyn’s CEO, Dr. Jacob Lalezari stated, “Our HIV protocol h